The growing demand for peptides and heparin across the pharmaceutical industry has played an integral role in market growth. The medical industry has invested palpable revenues towards analysing the action of peptides. Besides, relevance of peptides in drug development has also garnered the attention of the pharmaceutical industry. Several market analysts concur with the economic viability of using peptides in drug development. Mounting costs of active drug ingredients has shifted the medical industry’s focus towards the use of peptides. Considering the factors stated above, it is safe to predict that the global peptides and heparin market would accumulate substantial revenues in the years to follow.

This article elucidates several trend and dynamics pertaining to the growth of the global peptides and heparin market. Factmr estimates that the global peptides and heparin market would accumulate revenues worth US$ 34,000 Mn by the end of 2026. Furthermore, the expected CAGR of this market over the period between 2017 and 2026 is estimated at 8.10%. Key advancements across the pharmaceutical industry is behind the stellar growth rate of the peptides and heparin market.

Request for Sample Report with Statistical Info @

Rising Incidence of Chronic Diseases to Drive Demand

Research laboratories have expounded several uses of peptides in the medical industry. These laboratories have also delved into the details of various protein structures. Therefore, the applications of peptides have become evident across the medical sector.  Rising incidence of diabetes, cancer, and cardiovascular diseases could also aid the growth of the global market. Research related to anti-cancer drugs involves the use of lithium heparin, while ammonium heparin is used for cardiovascular treatment drugs. The collective demand for heparin and peptides across the medical and healthcare industry shall unfurl fresh opportunities for market growth. Moreover, increasing investments in medical research shall also help in attracting fresh revenues in the market.

Need for Efficient Treatment of Thromboembolic Disorders

Use of heparin in treatment of blood coagulation has garnered the attention of the medical fraternity. The rising incidence of venous diseases is expected to drive demand for heparin across the medical industry. Besides, cases of thromboembolic disorders have also increased over the past decade. Focus of the medical industry towards treating and managing such disorders has generated humongous revenues within the global peptides and heparin market. The efforts of the Food and Drug Administration (FDA) to popularise several important drugs shall be a harbinger of market growth.

A new research developed a distinct peptide that could help in disrupting a protein complex that triggers post-traumatic stress disorder (PTSD). This could help in preventing patients from recalling fear memories, while making way for new treatment lines for PTSD. The study was published in the Journal of Clinical Investigation, and it gives important cues for the medical research fraternity.

For More Detailed Information about Methodology @

Availability of Substitutes for Heparin

Despite favourable growth prospects, limited bioavailability of heparin could cause roadblocks for the market vendors. Moreover, side effects of heparin have also raised several concerns regarding its usage. Protamine sulphate is used as an alternative to heparin, and growing popularity of the former could also be a challenge for the vendors. However, the collective relevance of peptides and heparin in the medical industry shall continue to propel overall market demand.

Some of the prominent vendors operating in the global peptides and heparin market are Biofer S.p.A,, Celsus, Hemmo Pharma, Wockhardt Ltd., AmbioPharm, Inc., Sun Pharmaceutical Industries Ltd., and Abbott Laboratories. 

Media Release-